Form 4 UroGen Pharma Ltd. For: Jun 04 Filed by: Schoenberg Mark
Last urogen pharma ltd earnings: 11/12 08:00 am
Check Earnings Report
US:NASDAQ Investor Relations: investors.urogen.com
| Impact snapshot | Event time: | URGN | ||||
|---|---|---|---|---|---|---|
|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last price | ||
| VWAP | ||
|
High:
|
Max up |
High:
|
|
Low:
|
Max down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event Day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance Since Event
Time and Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
SIGN UP TODAY
Opt-in for
URGN alerts
URGN alerts
from News Quantified
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
URGN alerts
High impacting UroGen Pharma Ltd news events
Weekly update
A roundup of the hottest topics
URGN
News
- Urogen Pharma Ltd (NASDAQ: URGN) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating.MarketBeat
- Urogen Pharma Ltd (NASDAQ: URGN) had its "buy" rating re-affirmed by analysts at Cowen Inc.MarketBeat
- Urogen Pharma Ltd (NASDAQ: URGN) had its price target lowered by analysts at Oppenheimer Holdings Inc. from $62.00 to $52.00. They now have an "outperform" rating on the stock.MarketBeat
- Urogen Pharma Ltd (NASDAQ: URGN) is now covered by analysts at National Securities. They set a "neutral" rating on the stock.MarketBeat
- UroGen to Present at 38th Annual J.P. Morgan Healthcare ConferenceBusiness Wire
- More
URGN
SEC Filings
- 1/7/20 - Form 4
- 1/3/20 - Form EFFECT
- 1/2/20 - Form 424B5
- URGN's page on the SEC website
- More